Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875582 | 0.89 | CCR5 (0.36) | SIRT2SIRT1PLA2G2AALDH1A1ADAMTS5 | |
| SCHEMBL7083990 | 0.89 | ADAMTS5 (0.33) | SIRT2SIRT1PLA2G2AALDH1A1ADAMTS5 | |
| SCHEMBL4875551 | 0.87 | CHRM2 (0.36) | ALDH1A1 | |
| SCHEMBL4876417 | 0.87 | GPR119 (0.39) | HRH2HRH1 | |
| SCHEMBL4872326 | 0.87 | CYP3A4 (0.34) | ALDH1A1ADAMTS5 | |
| SCHEMBL4873761 | 0.85 | RORC (0.34) | PLA2G2AALDH1A1ADAMTS5PTGS2 | |
| SCHEMBL4872361 | 0.85 | GPR119 (0.33) | — | |
| SCHEMBL4870335 | 0.85 | GPR119 (0.36) | HRH2HRH1 | |
| SCHEMBL4870274 | 0.85 | GPR119 (0.36) | HRH2HRH1PLA2G2A | |
| SCHEMBL4874334 | 0.85 | GPR119 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094778-B2 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | HRH2 118/4885HRH1 136/4885DPP4 1598/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | HRH2 87/4885HRH1 106/4885DPP4 1485/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | HRH2 87/4885HRH1 106/4885DPP4 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.